Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Wells

Critical Care Medicine Grand Rapids, MI Medical Doctor

NPI 1497791610 CMS profile 918179

4100 Lake Dr Se, Ste 200, Grand Rapids, MI 49546

Open in the dashboard

General payments

$7,610

18 records reported · program years 2019–2025

Research payments

$615

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,821,466 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Jason Wells of Grand Rapids, MI is reported in the CMS Open Payments database as having received $7,610 across 18 general payments and $615 in research payments paid to them. Separately, studies naming them as principal investigator received $2,821,466 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $130 4
2024 General $1,232 6
2023 General $129 3
2022 General $2,980 2
2022 Research $358 2
2021 General $3,000 1
2021 Research $256 2
2019 General $139 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Wells
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Jason Wells were reported at $130. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Jason Wells Critical Care Medicine median Middle half National median
2019 $139 $149 $51–$535 $163
2020 $0 $110 $30–$325 $114
2021 $3,000 $125 $34–$403 $132
2022 $2,980 $157 $49–$582 $149
2023 $129 $162 $56–$621 $160
2024 $1,232 $168 $53–$634 $164
2025 $130 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius USA Marketing, Inc. $7,070 7 payments
  2. Amgen Inc. $180 1 payment
  3. Edwards Lifesciences Corporation $123 1 payment
  4. Verona Pharma, Inc. $75 1 payment
  5. AstraZeneca Pharmaceuticals LP $52 3 payments
  6. Medtronic, Inc. $31 1 payment
  7. Argenx US, Inc. $24 1 payment
  8. GlaxoSmithKline, LLC. $24 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $18 1 payment
  10. Genzyme Corporation $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $3,000 1 payment
  2. Consulting Fee $2,800 1 payment
  3. Food and Beverage $1,310 13 payments
  4. Travel and Lodging $500 3 payments
Products named General payments · program years 2019–2025
  1. NOVALUNG SYSTEM Heart and Lung Therapies $2,876 2 payments
  2. TEZSPIRE $180 1 payment
  3. EV1000 Clinical Platform $123 1 payment
  4. NOVALUNG SYSTEM Heart and Lung Therapies $76 1 payment
  5. Ohtuvayre $75 1 payment
  6. HVAD PUMP IMPLANT KIT $31 1 payment
  7. VYVGART Hytrulo $24 1 payment
  8. VYVGART $24 1 payment
  9. NUCALA $24 1 payment
  10. FASENRA $21 1 payment
  11. Other $45 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $615 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

290

Median for Pulmonary Disease: 936

Drug cost

$245,053

Median for Pulmonary Disease: $487,987

Branded share of claims

88.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 34 $109,481
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 134 $102,403
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 24 $13,398
Breo Ellipta Fluticasone/Vilanterol Brand 16 $9,621
Sildenafil Citrate Generic 19 $5,208
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 11 $3,114
Albuterol Sulfate Hfa Albuterol Sulfate Brand 38 $1,764
Prednisone Generic 14 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$108,288

Medicare's payments for the services billed

Medicare patients

170

Average age 70

Services billed

3,347

87 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 47%
Ischemic heart disease 40%
Arthritis 40%
COPD 39%
Depression 39%
Atrial fibrillation 35%
Diabetes 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $24
$24 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record